Custom Application Development Service Market to grow by USD 53.7 Billion from 2025-2029, driven by cloud adoption, AI's impact on market trends
Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF
Custom Application Development Service Market Scope
Report Coverage
Details
Base year
2024
Historic period
2019 - 2023
Forecast period
2025-2029
Growth momentum & CAGR
Accelerate at a CAGR of 9.4%
Market growth 2025-2029
USD 53.7 billion
Market structure
Fragmented
YoY growth 2022-2023 (%)
8.4
Regional analysis
North America, Europe, APAC, South America, and Middle East and Africa
Performing market contribution
North America at 37%
Key countries
US, China, Germany, UK, Canada, India, France, Japan, Brazil, and UAE
Key companies profiled
Accenture PLC, Appinventiv Technologies Pvt. Ltd., Capgemini Services SAS, Chetu Inc., Cognizant Technology Solutions Corp., Datamatics Global Services Limited, DXC Technology Co., Fujitsu Ltd., HCL Technologies Ltd., Iblesoft Inc., Infanion, Infosys Ltd., International Business Machines Corp., LTIMindtree Ltd., NTT DATA Corp., Radixweb, ScienceSoft USA Corp., Software AG, Speridian Technologies, and Wipro Ltd.
Market Driver
Custom application development services are on the rise, with a focus on industry-specific applications and real-time data analysis. Flexible workspaces and remote work are becoming the norm, leading to cost reduction and increased agility. AI-driven chatbots and robotics automation are enhancing business processes in various sectors, including investment banking. Cloud technology is a major trend, with cloud-based software development, centralized systems, and web-based solutions offering ease of access, flexibility, and cost-effectiveness. Analytical tools and business intelligence (BI) are essential for large enterprises and SMEs in IT & telecom, retail, and other sectors, providing insights for decision-making and inventory cost reduction. Security is a top concern, with cyberattacks and cybercrimes on the rise. Investment in cyber insurance and AI, IoT, machine learning, and blockchain technologies is essential for data security. Open-source programs offer intellectual property advantages, but come with security risks. Features and functions of corporate software are evolving, with automation, performance, and scalability key priorities. Remote access and real-time information are essential for businesses in the retail, grocery, and food delivery sectors. Cloud deployment ensures reliability and data security. Mobile apps and IoT systems are transforming industries, with IoT investments in devices and analytics capabilities driving innovation. Smart technology and design are essential for user experience and adoption. Ultimately, custom application development services offer businesses a competitive edge, enabling them to streamline processes, reduce costs, and make informed decisions.
The custom application development service market is witnessing a significant trend with the increasing adoption of Low-Code Development Platforms (LCDPs). These platforms enable developers to build applications with minimal hand-coding, utilizing visual interfaces and drag-and-drop features. This accelerates the development process, allowing businesses to launch custom applications swiftly and efficiently compared to conventional coding methods. LCDPs abstract much of the software development intricacies, making it more accessible to non-technical users, such as business analysts and subject matter experts. By involving these stakeholders in the application development process, the need for specialized IT resources is reduced. The architecture and design of company systems are crucial in shaping the entire process and lifecycle of enterprises.
Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution!
Market Challenges
Custom application development services help businesses create unique software solutions tailored to their industry applications. Challenges include real-time data analysis, flexible workspaces, AI-driven chatbots, robotics automation, and remote work. Cost reduction is a significant factor, with analytical tools and business intelligence (BI) essential for decision-making. Investment banking, retail, IT & telecom segments, and SMEs all benefit from cloud technology's agility, performance, and cost-effectiveness. Cloud-based software development enhances scalability, integration, and security. Open-source programs offer flexibility, but IP protection is crucial. Cross-departmental communication and automating processes are key. Industry-specific challenges include inventory costs, cyberattacks, and cybercrimes, requiring cyber insurance. Features like AI, IoT, machine learning (ML), Blockchain, robots, and data science are essential. Cloud deployment ensures ease of access and real-time information. Remote access and real-time information are vital for large enterprises and SMEs alike. Security, reliability, and data security are non-negotiable. Mobile apps, retail stores, grocery stores, and food delivery services all require customized solutions. In summary, custom application development services address industry-specific challenges, offering features like AI, IoT, ML, and Blockchain, while ensuring security, scalability, and cost-effectiveness. Cloud technology and open-source programs offer flexibility and agility, making them ideal solutions for businesses in various sectors.
Open-source software platforms, such as Apache NetBeans, Apache Cordova, Eclipse IDE, and Bootstrap, offer free use and development resources for application creators. These platforms, built by and for communities of software engineers, are easily accessible on web portals. Their availability negatively impacts the revenue of proprietary application development service providers. End-users benefit from open-source software through free support, prevention of vendor lock-in, and adherence to open standards. These systems, like Apache NetBeans and Eclipse IDE, are distributed version control systems, ensuring efficient application development.
Discover how AI is revolutionizing market trends- Get your access now!
Segment Overview
This custom application development service market report extensively covers market segmentation by
Deployment
1.1 On-premise
1.2 Cloud
End-user
2.1 Large enterprises
2.2 SMEs
Geography
3.1 North America
3.2 Europe
3.3 APAC
3.4 South America
3.5 Middle East and Africa
1.1 On-premise- Custom application development services refer to the creation of unique software solutions tailored to meet specific business requirements. On-premise deployment is a popular choice for these services, offering clients full control over their hardware and software. However, on-premise deployment comes with higher upfront costs compared to cloud deployment, which requires recurring monthly payments. Additionally, on-premise deployment offers greater data security as clients have single access points and control over their servers and data. Large companies dealing with sensitive business information often opt for on-premise application development services due to the enhanced security features. For instance, Infosys Ltd. (Infosys) helped Anglian Water develop an on-premise custom application to ensure product quality. Despite the advantages, the use of on-premise application development services is expected to decrease during the forecast period due to the high capital expenditure associated with maintaining internal servers. This trend will contribute to the growth of the global custom application development service market, as more businesses shift towards cloud-based solutions.
Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics
Research Analysis
Custom Application Development Service Market: Custom software development is a dynamic industry that caters to the unique needs of businesses across various sectors. The market encompasses industry applications, real-time data analysis, flexible workspaces, and advanced technologies like AI-driven chatbots and robotics automation. Remote work and cost reduction are key drivers, with analytical tools and business intelligence (BI) enabling data-driven decision-making. Machine learning and artificial intelligence are transforming business processes in sectors like investment banking, IT & telecom, and retail. Features such as real-time analytics, cross-departmental communication, and automating processes are essential. Analytics software, cloud technology, mobile apps, and services for grocery stores, grocery delivery services, and food delivery services are significant market segments. The market's continuous evolution ensures the delivery of innovative solutions that meet evolving business needs.
Market Research Overview
The Custom Application Development Service Market is a dynamic and evolving industry that caters to the unique software needs of businesses across various sectors. This market encompasses the development of industry applications, including real-time data analysis, flexible workspace solutions, and AI-driven chatbots. Robotics automation and remote work are also key areas of focus, offering cost reduction and enhanced performance through analytical tools and business intelligence (BI) solutions. Cloud technology plays a significant role in this market, with cloud-based software development, centralized systems, and web-based solutions enabling scalability, integration, and real-time information access. Agile methodologies and open-source programs ensure flexibility and cost-effectiveness. Key applications include investment banking, retail, IT & telecom, and SMEs. Features such as automating processes, inventory cost reduction, and decision-making capabilities are essential for businesses looking to enhance profitability and remain competitive. Security risks, including cyberattacks and cybercrimes, necessitate investment in cyber insurance and advanced security measures. IoT, AI, machine learning, and blockchain technologies are driving innovation in this market, with smart technology and data science at the forefront. Revelation of IoT systems, IoT investments, and IoT devices are transforming industries and creating new opportunities for custom application development services.
Table of Contents:
1 Executive Summary2 Market Landscape3 Market Sizing4 Historic Market Size5 Five Forces Analysis6 Market Segmentation
Deployment
End-user
Geography
7 Customer Landscape8 Geographic Landscape9 Drivers, Challenges, and Trends10 Company Landscape11 Company Analysis12 Appendix
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio ResearchJesse MaidaMedia & Marketing ExecutiveUS: +1 844 364 1100UK: +44 203 893 3200Email: media@technavio.comWebsite: www.technavio.com/
View original content to download multimedia:https://www.prnewswire.com/news-releases/custom-application-development-service-market-to-grow-by-usd-53-7-billion-from-2025-2029--driven-by-cloud-adoption-ais-impact-on-market-trends---technavio-302362944.html
SOURCE Technavio
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hypebeast
7 hours ago
- Hypebeast
The Slow Death of the Contemporary Art Gallery
The contemporary art gallery as we know it is dying. In cities like New York and Los Angeles, dedicated spaces that once buzzed with foot traffic and formal openings are now struggling with rising rents and changing expectations. The old model, where a gallery does everything for its artists, feels like it's falling apart. Big gallery chains, the ones built on endless art fairs, multiple cities and huge rosters of artists, are losing their grip. Last month, Tim Blum announced he would close his Blum & Poe galleries in L.A. and Tokyo and even stop plans for a new one in Tribeca. He was blunt about the reason: 'This is not about the market. This is about the system,'he told ARTnews, pointing out that collectors have more power than ever to negotiate. His decision echoes a wider feeling across the industry with many giving up on the idea of building giant gallery empires. You can see this shift happening at major events. The latestArt Baselconfirmed that galleries are showing more mid-priced work, not just the massive, ultra-expensive pieces they once counted on. A recentreport from Art Basel and UBSshowed that while the overall art market shrank last year, the number of actual sales went up. It's a clear signal that the business is no longer just about a small group of big spenders, it's now about reaching a wider audience at lower price points. 'The old model was built on scarcity and prestige. The new one runs on access and attention.' A significant force behind this change is the shifting demand for different types of art. The once-dominant 'blue-chip' artists, masters whose work commanded staggering prices, are no longer the only game in town. Collectors are increasingly turning their attention to 'red-chip' artists, a new class of talents whose value is built on viral hype and cultural relevance rather than institutional endorsement. These artists are attractive for two main reasons: their work is often more accessible and affordable, and it brings fresh, diverse cultural perspectives that feel relevant and exciting to a global audience. This hunger for new voices and unconventional methods is reshaping the market. A key example isOlaolu Slawn, a London-based artist who sold out his solo show,I present to you, Slawn, at the Saatchi Yates gallery in 2024 by creating and selling 1,000 individual, more accessible pieces, an approach that challenges the fine art world's focus on scarcity and prestige. A separate but related trend sees celebrities entering the art market with their own work, often commanding high prices based on their fame. Actor Adrien Brody is a notable example. His art, which he described is about celebrating the little nuances in life has sold for significant amounts, as per a convo withInterview Magazine. For instance, a painting he created of Marilyn Monroe was sold at a Cannes gala auction for $425,000 USD, illustrating how star power can directly translate into commercial value. However, his work has drawn sharp criticism from the industry, with critics often labeling it as kitschy and derivative. One critic writing forARTnewsdescribed his work as having a 'faux naïve aesthetic' and 'mediocre production value,' while others have accused him of cheaply appropriating the styles of Jean-Michel Basquiat and Andy Warhol. As the old guard shrinks, smaller galleries are finding new ways to thrive. In New York,Tiwa Galleryshows self-taught artists in a relaxed space, rejecting flashy Landddcombines Latin American crafts with immersive events. In L.A.,Marta galleryblends art and design right into everyday life. These new spaces care more about quiet, genuine connection than putting on a spectacle. Retail is also becoming a new kind of gallery. Stores like South Korea's Gentle Monster and London's Dover Street Market are blurring the lines between art and commerce, transforming shopping into an immersive cultural experience. Gentle Monster's stores are famous for their fantastical, ever-changing installations, from surreal kinetic sculptures to robotic figures that draw in visitors who are just as interested in the art as they are in the eyewear. Dover Street Market, founded by Comme des Garçons's Rei Kawakubo, is a 'beautiful chaos' where each brand and artist is given a dedicated space to create a unique installation, turning the store into a constantly evolving exhibition. By blending high-end retail with cutting-edge art and design these spaces offer a new kind of public access to creativity, making the gallery experience a part of a commercial transaction rather than a separate cultural outing. 'If your space is fueled by DJs and cocktails, maybe it isn't really a gallery anymore.' It's clear that going to a gallery is no longer the only way to see or buy art. Today, buyers can just scroll on their phones and purchase work directly from studios or social media. This instant access has replaced the slow dance of white-cube shows and champagne previews. Some galleries are trying to keep up, creating online art drops and hosting pop-ups in different retail spaces. But others are pushing back, as one veteran gallerist puts it: if your space is fueled by DJs and cocktails, maybe it isn't really a gallery anymore. Art isn't disappearing. It's just moving, becoming more accessible and less tied to one physical location. The old model was built on scarcity and prestige. The new one runs on access and attention. The question isn't whether galleries will survive, but which ones can change fast enough to matter.
Time Business News
11 hours ago
- Time Business News
Next-Generation Approaches to Hematologic Malignancies
Hematologic malignancies are cancer that affect blood, bone marrow, and lymphatic systems including leukemia, lymphoma and multiple myeloma. These cancers disrupt normal blood cell production and immune function. The growth of the hematologic malignancy market is inspired by increasing the prevalence of global cancer, increasing target remedies and immunotherapy, progression in clinical technologies and expanding research in individual medicine. Additionally, increasing awareness, better healthcare infrastructure, and oncology contribute to more investment market expansion in drug development. Key Growth Drivers and Opportunities Increasing the Prevalence of Global Cancer: The increasing global spread of cancer greatly enhances the growth of the market of hematologic malignancies, as blood -related cancer, such as leukemia, lymphoma and multiple myeloma, become a large part of cancer worldwide. As more individuals are affected by these conditions, there is an increasing demand for accurate diagnosis, advanced treatment options and long -term disease management solutions. In cases, this increase encourages drug companies and research institutes to invest in innovative remedies such as targeted treatment, immunotherapy and CAR-T cell therapy. Additionally, high cancer phenomena motivate governments and healthcare systems to increase screening programs and to reach oncology. Challenges Hematologic malignancies markets face several borders, including high cost of advanced treatments such as car-T cell treatment and targeted drugs, which can restrict access to patients in low- and moderate-income areas. Complex regulatory approval, long clinical testing procedures, and severe side effects or ability to resist also face significant challenges. Additionally, limited availability of specialized clinical equipment and lack of efficient health care professionals in some fields obstruct timely and accurate diagnosis, overall treatment affects results and slows down market development. Innovation and Expansion Kyowa Kirin and Kura Oncology Collaborate to Create Ziftomenib for Acute Leukemias In November 2024, in order to develop and market ziftomenib, Kura's selective oral menin inhibitor, which is being researched for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies, Kura Oncology, Inc. and Kyowa Kirin Co., Ltd. announced they have formed a global strategic partnership. Kura will get USD 330 million up front as part of the deal, and it anticipates receiving up to USD 420 million in near-term milestone payments, including one when ziftomenib is introduced in the monotherapy relapsed/refractory (R/R) context. Merck Launched Phase III Trials for Novel Treatments for Blood Disorders and Cancer In January 2024, With the start of pivotal Phase III studies for four new candidates for solid tumors and hematologic malignancies, Merck's strong oncology and hematology portfolio is progressing. Essential thrombocythemia (ET), small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia (CLL), non-small cell lung cancer (NSCLC), some patients with endometrial carcinoma who have already received treatment, and metastatic castration-resistant prostate cancer (mCRPC) are among the conditions for which the company announced active enrollment for investigational medications. The firm is committed to ongoing research to broaden our portfolio of oncology treatments in order to continue addressing unmet needs in cancer care. The company has a rich history of transforming groundbreaking science into medicines that save and enhance lives worldwide. Inventive Sparks, Expanding Markets The key players operating the hematologic malignancies market includes, Johnson & Johnson Services Inc., Pfizer Inc., Novartis AG, AbbVie Inc., GlaxoSmithKline PLC., Bristol-Myers Squibb Company, Glenmark Pharmaceuticals Inc., Celgene Corporation, F. Hoffman-La Roche Ltd., Takeda Pharmaceutical Company Limited., and others. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
Yahoo
13 hours ago
- Yahoo
Oligonucleotide CDMO Market to Soar USD 18.37 Billion at 21.83% Strong CAGR by 2034
The global oligonucleotide CDMO market is valued at USD 3.11 billion in 2025 and is projected to reach approximately USD 18.37 billion by 2034, expanding at a CAGR of 21.83% over the forecast period. Ottawa, Aug. 08, 2025 (GLOBE NEWSWIRE) -- According to a study by Towards Healthcare, a sister company of Precedence Research, the global oligonucleotide CDMO market size to grow from USD 2.55 billion in 2024 and is expected to expand USD 18.37 billion by 2034. The growth of the market is driven by the increased demand for specialized techniques, which are technologically advanced due to the growing prevalence of chronic diseases in the region. The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ Key Takeaways North America dominated the oligonucleotide CDMO market in 2024. Asia Pacific is estimated to grow at the fastest CAGR during the forecast period. By service, the contract manufacturing segment led the market in 2024. By service, the contract development segment is estimated to achieve significant growth during the forecast period. By type, the ASO segment held a significant share of the market in 2024. By type, the siRNA segment is expected to grow significantly during the forecast period. By application, the therapeutic segment held the largest share of the oligonucleotide CDMO market in 2024. By application, the research segment is anticipated to grow at a significant rate during the forecast period. By end-use, the pharma segment held a major share of the market in 2024. By end-use, the biotech segment is anticipated to achieve a significant share of the market during the forecast period. Market Overview & Potential An oligonucleotide CDMO (Contract Development and Manufacturing Organization) specializes in offering comprehensive services for developing and manufacturing short oligonucleotides, which are synthetic nucleic acid sequences used in various biotech and pharmaceutical applications. These organizations provide expertise in custom synthesis, process development, scale-up, and GMP manufacturing of oligonucleotides. You can place an order or ask any questions, please feel free to contact us at sales@ What Is the Growth Potential Responsible for The Growth of The Oligonucleotide CDMO Market? The growth of the market is driven by the growing demand for personalized medicines and RNA therapeutics, which demand specialized manufacturing capabilities, which fuels the growth of the market. The increasing prevalence of chronic diseases, especially cancer and cardiovascular diseases, with advancements in oligonucleotide manufacturing to improve synthesis technologies with automated techniques, drives the growth of the market. Other key growth drivers are government support and funding, increased investment in biotechnology, globalization, and increased collaboration boost the growth of the market. What Are the Emerging Trends in the Oligonucleotide CDMO Market? Growing Demand for Oligo-based Therapies: Oligonucleotides, including antisense oligonucleotides and small interfering RNAs, are increasingly recognized as therapeutic agents because of their targeted action and specificity. Focus on Precision Medicine: The shift toward personalized treatments designed for individual patients is boosting the need for specialized oligonucleotide therapies. Increased FDA Approvals: The rising number of FDA approvals for oligonucleotide-based drugs, such as Qalsody for ALS, further fuels market growth and stimulates innovation. Cost Efficiency and Expertise: Outsourcing to CDMOs enables companies to utilize specialized knowledge and potentially lower costs associated with in-house manufacturing, particularly for complex processes. What Are the Major Challenges Facing the Oligonucleotide CDMO Market? The market encounters several notable challenges, mainly due to manufacturing complexity, regulatory obstacles, and the need for advanced expertise and infrastructure. Scaling from research to commercial volumes, achieving high purity, and ensuring delivery efficiency to target sites are significant hurdles. Evolving regulatory requirements and the need for specialized skills in oligonucleotide synthesis, purification, and conjugation also contribute to the difficulty. Get the latest insights on life science industry segmentation with our Annual Membership: Regional Insights Why Did North America Lead the Oligonucleotide CDMO Market in 2024? North America held a dominant position in 2024 due to its well-established research facilities, substantial R&D investments in peptide and oligonucleotide therapies, and a higher prevalence of chronic diseases. The demand for biopharmaceuticals like oligonucleotides and peptides supports this growth. North American CDMOs are well-equipped to meet this demand by providing specialized development and manufacturing services for these complex compounds. The market expansion is driven by ongoing investments from pharmaceutical and biotech firms into R&D, often through partnerships with CDMOs to access advanced infrastructure and expertise. High R&D investment, advanced biotech infrastructure, rising chronic disease prevalence, and strong pharmaceutical industry demand drive U.S. oligonucleotide CDMO growth. Regulatory clarity from the FDA, increasing personalized medicine focus, and government support for genomics research further enhance market expansion, fostering innovation and strategic collaborations with contract manufacturers. Government incentives for biotechnology, a skilled scientific workforce, and growing demand for precision medicine propel Canada's oligonucleotide CDMO sector. Strong academic-industry partnerships, supportive regulatory frameworks, and increasing investments from global pharma companies in Canadian CDMO facilities promote innovation, clinical trials, and manufacturing scalability within the country. Why Is Asia Pacific Projected to Show Rapid Growth in the Oligonucleotide CDMO Market? Asia Pacific is anticipated to be the fastest-growing region for oligonucleotide CDMOs during the forecast period. Countries like China, Japan, India, and South Korea are leading due to their large populations, focus on biopharmaceutical innovation, and strong healthcare investments. The region's market share has notably increased over recent years, supported by economic growth and rising prosperity, making it attractive for pharmaceutical outsourcing. This growth is further fueled by increased R&D funding and improvements in healthcare infrastructure. Rapid biotechnology expansion, government funding, and a large patient population fuel oligonucleotide CDMO growth in China. Domestic pharma companies increasingly outsource production, while favorable policies, infrastructure development, and cost advantages attract global partnerships. China's focus on RNA therapeutics and local innovation also accelerates CDMO sector maturation and competitiveness. Low manufacturing costs, a strong generic pharmaceutical base, and a growing talent pool drive India's oligonucleotide CDMO growth. Government initiatives supporting biotech innovation, rising contract research demand, and increased interest from Western firms in Indian CDMOs contribute. The expanding clinical trial ecosystem further enhances market attractiveness and outsourcing potential. Become a valued research partner with us - Segmental Insights Which Service Segment Dominated the Oligonucleotide CDMO Market in 2024? The contract manufacturing segment led the market in 2024, driven by the rising need for wide-scale, cGMP-compliant oligonucleotide APIs for clinical and commercial use. To meet the growing demand for ASOs, siRNAs, and mRNA-based therapies, CDMOs equipped with advanced solid-phase synthesis, automated fill-finish systems, and high-throughput purification are vital. This leadership is reinforced by pharmaceutical companies' reliance on CDMOs for high-purity, scalable, and globally compatible manufacturing solutions, driven by strict regulations and expansion challenges. This led to a growing and expanding influence on market growth. The contract development segment is estimated to achieve significant growth during the forecast period. Encompassing services like preclinical development, formulation, process development, and analytical techniques. These services are crucial for optimizing production processes and ensuring the safety and quality of oligonucleotides and peptides. R&D in oligonucleotide therapies is a key investment focus for pharma and biotech companies. Partnering with CDMOs allows these companies to reduce costs and accelerate product development, focusing on their core competencies. How did ASO Segment Dominated the Oligonucleotide CDMO Market in 2024? The ASO segment held a significant share of the market in 2024. Over the decades, the biotech and pharma industries have developed innovative approaches to target disease-related proteins, demanding innovation and development of new technologies and forms of products, which increases the demand for the market. RNA therapeutics, especially antisense oligonucleotides, have made significant progress in the market. Several ASO-based drugs are already FDA-approved, with many more under clinical testing. These factors support the growth and expansion of the market. The siRNA segment is expected to grow significantly during the forecast period. SiRNA technologies offer speed and specificity, helping to overcome preclinical drug development hurdles, which fuels the demand for the market. They currently assist in identifying the most promising pharmacological targets for specific diseases and are being explored for new, potent applications in drug candidate prioritization. These applications and benefits offered by the segment promote the growth and expansion of the market. Which Application Segment Dominated the Oligonucleotide CDMO Market in 2024? The therapeutic segment held the largest share of the market in 2024. Approaches have been developed to enhance the pharmacokinetics and pharmacodynamics of oligonucleotides. Historically targeted at rare diseases and niche markets, oligonucleotides now benefit large patient groups. The field is rapidly expanding despite fluctuations, with 44 companies having compounds in late-stage clinical trials or on the market. Major players include Johnson & Johnson, Roche, Novartis, and AstraZeneca, alongside specialized biotech firms like Ionis Pharmaceuticals and Alnylam Pharmaceuticals. Concurrently, there has been notable activity in oligonucleotide patents and applications influencing the growth. The research segment is anticipated to grow at a significant rate in the oligonucleotide CDMO market during the forecast period, with contributions from research institutions impacting early-stage research, innovative technologies, and scientific breakthroughs. These institutions are vital in identifying therapeutic potentials, fostering partnerships with CDMOs and pharma companies, and influencing market dynamics. Advances in distribution, analytics, and synthesis are driving market expansion, and published research influences development and manufacturing strategies. How did the pharma Segment dominate the Oligonucleotide CDMO Market In 2024? The pharma segment accounted for a major market share in 2024. The advent of oligonucleotide therapies has revolutionized medicine, with several approved in the US and EU. These include a mix of single and double-stranded polydeoxyribonucleotides, six siRNAs, twelve ASOs, and one aptamer. The growing pharma sector and the application of oligonucleotides increase the demand for manufacturing and production, which contributes to the growth and expansion of the market. The biotech segment is also expected to claim a significant market share, enabled by protein-DNA functionalization through covalent bonding. This technology facilitates the creation of therapeutic molecules with potential applications for diseases like AIDS and cancer. The ongoing research and development in the biotech sector further propels the growth and expansion of the market. Recent Developments in the Oligonucleotide CDMO Market In April 2025, Sumitomo Chemical announced the launch of its new company, Sumitomo Chemical Advanced Medical Solutions America LLC, in Massachusetts to serve as its Oligonucleotide CDMO2 business. The company will provide gRNA samples to customers by August 2025. In July 2024, Agilent Technologies announced a strategic agreement to acquire BioVectra, a specialized CDMO, for $925 million. The acquisition was made to build Agilent Technologies' CDMO specialization in oligonucleotides and CRISPR therapeutics, expanding its portfolio of services and bringing world-class capabilities to support gene editing. Browse More Insights of Towards Healthcare: The global life science CDMO market is witnessing rapid expansion, with revenues projected to reach several hundred million dollars by the end of the forecast period (2025–2034). The veterinary CRO and CDMO market was valued at USD 7.17 billion in 2024, is expected to reach USD 7.77 billion in 2025, and is projected to climb to approximately USD 16.13 billion by 2034, growing at a CAGR of 8.43% during 2025–2034. The advanced therapy medicinal products (ATMP) CDMO market stood at USD 6.73 billion in 2024, increased to USD 7.99 billion in 2025, and is forecast to surge to USD 37.27 billion by 2034, registering a CAGR of 18.82% from 2025 to 2034. The investigational new drug CDMO market was valued at USD 5.29 billion in 2024, rose to USD 5.66 billion in 2025, and is anticipated to reach USD 10.34 billion by 2034, expanding at a CAGR of 6.97% between 2025 and 2034. The mRNA therapeutics CDMO market was worth USD 4.62 billion in 2024, increased to USD 5.15 billion in 2025, and is projected to grow to USD 13.63 billion by 2034, recording a CAGR of 11.37% during 2025–2034. The CDMO services for pharma and biotech market is experiencing substantial growth from 2024 to 2034, fueled by the increasing outsourcing trend among pharmaceutical and biotechnology companies. The CDMO aseptic filling solutions market is set for strong growth throughout the forecast period, driven by rising demand for sterile manufacturing capabilities and specialized injectable therapies. The active pharmaceutical ingredients (API) CDMO market was valued at USD 127.45 billion in 2024, increased to USD 136.92 billion in 2025, and is estimated to reach USD 260.98 billion by 2034, growing at a CAGR of 7.43% from 2025 to 2034. The small molecule CDMO market stood at USD 72.81 billion in 2024, rose to USD 78.01 billion in 2025, and is forecast to hit USD 145.12 billion by 2034, expanding at a CAGR of 7.14% during 2025–2034. The topical drugs CDMO market was worth USD 46.32 billion in 2024, increased to USD 51.62 billion in 2025, and is expected to reach USD 136.71 billion by 2034, registering a CAGR of 11.43% between 2025 and 2034. Top Companies and Their Contributions to the Market Contributions & Offerings to the Oligonucleotide CDMO Market Bachem A global leader in peptide and oligonucleotide synthesis, Bachem offers full CDMO services including development, GMP manufacturing, and analytics. Thermo Fisher Scientific Inc. Provides end-to-end oligonucleotide services, from preclinical to commercial scale, leveraging advanced technologies and global infrastructure. Agilent Technologies, Inc. Offers custom oligo synthesis and quality control platforms, supporting therapeutic development with scalable manufacturing capabilities. EUROAPI Delivers active pharmaceutical ingredient (API) production, including oligonucleotides, with a focus on quality, sustainability, and innovation. ST Pharm Specializes in large-scale GMP oligonucleotide manufacturing, supplying APIs globally with expertise in modified nucleic acids and cGMP compliance. Kaneka Eurogentec S.A. Provides custom manufacturing of therapeutic oligonucleotides, with cGMP-grade synthesis, formulation, and analytical support. Ajinomoto Co., Inc. Leverages proprietary biotechnologies for oligonucleotide production, offering scale-up and process development through its CDMO division. Aurigene Pharmaceutical Offers integrated CDMO services including oligonucleotide synthesis, analytical development, and GMP manufacturing for global biopharma clients. Syngene International Provides end-to-end oligo development and manufacturing, supporting early-stage to commercial scale with regulatory expertise. PolyPeptide Group Recently expanded into oligonucleotide CDMO services, combining peptide and oligo synthesis capabilities with advanced regulatory compliance. Key Players in Oligonucleotide CDMO Market Bachem Thermo Fisher Scientific Inc. Agilent Technologies, Inc. EUROAPI ST Pharm Kaneka Eurogentec S.A. Ajinomoto Co., Inc. Aurigene Pharmaceutical Services Ltd. Syngene International Limited PolyPeptide Group WuXi AppTec Eurofins Scientific GenScript Lonza Danaher Corporation Segments Covered in The Report By Service Contract Manufacturing Clinical Commercial Contract Development By Type ASO siRNA CPG Oligos gRNA By Application Therapeutic Research Diagnostics By End-User Pharma Biotech By Region North America U.S. Canada Asia Pacific China Japan India South Korea Thailand Europe Germany UK France Italy Spain Sweden Denmark Norway Latin America Brazil Mexico Argentina Middle East and Africa (MEA) South Africa UAE Saudi Arabia Kuwait Immediate Delivery Available | Buy This Premium Research @ Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway. Access the Dashboard: About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth. You can place an order or ask any questions, please feel free to contact us at sales@ Europe Region - +44 778 256 0738 North America Region - +1 8044 4193 44 Web: Find us on social platforms: LinkedIn | Twitter | InstagramError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
